Health
Ozempic and Wegovy Demand Has Drugmaker Novo Struggling to Keep Up
- Wegovy sales are soaring, but its availability is restricted
- Drugmaker raises profit, sales outlook on obesity-drug demand
This article is for subscribers only.
Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to expand production.
The Danish company made the comments even as it raised its profit and sales outlook for the year as demand for Wegovy and another related diabetes medicine fuel revenue growth. The stock fell as much as 2.2% in Copenhagen.